MGX Metagenomi Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1785279 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.7%
TTM net income YoY-10.2%
TTM EPS YoY-23.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-415.5%
Net margin-384.6%
FCF margin-392.0%
EBITDA margin-392.0%
Returns
ROE-49.0%
ROA-34.7%
ROIC (approx.)-49.5%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets30.0%
Debt / equity0.00x
Current ratio6.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.18M | — | $1.25M | $3.91M | $8.66M | $8.51M | $4.13M | $9.61M |
| R&D expense | $17.53M | $22.51M | $19.30M | $21.50M | $25.28M | $22.51M | $25.14M | $23.16M |
| SG&A expense | $6.88M | $6.00M | $6.54M | $6.78M | $6.21M | $6.99M | $6.80M | $7.07M |
| Operating income | -$22.23M | -$28.77M | -$24.59M | -$24.37M | -$22.84M | -$20.99M | -$27.82M | -$20.62M |
| Pretax income | -$21.13M | -$27.48M | -$23.05M | -$22.49M | -$20.63M | -$19.86M | -$24.94M | -$24.61M |
| Income tax | $0 | $0 | $10,000 | $34,000 | -$234,000 | $44,000 | $98,000 | -$1.21M |
| Net income | -$21.13M | -$27.48M | -$23.06M | -$22.53M | -$20.39M | -$19.91M | -$25.04M | -$23.40M |
| EBITDA | -$20.97M | -$27.51M | -$23.31M | -$23.07M | -$21.52M | -$19.65M | -$26.46M | -$19.16M |
| EPS (basic) | -0.56 | -0.73 | -0.61 | — | -0.55 | -0.54 | -0.68 | — |
| EPS (diluted) | -0.56 | -0.73 | -0.61 | — | -0.55 | -0.54 | -0.68 | — |
| Weighted avg. shares (diluted) | 37.78M | 37.66M | 37.58M | — | 37.35M | 37.16M | 37.02M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $36.11M | $39.03M | $25.31M | $41.72M | $32.77M | $26.85M | $29.20M | $32.63M |
| Short-term investments | $65.57M | $81.64M | $114.86M | $119.08M | $151.34M | $178.14M | $196.78M | $220.92M |
| Receivables | $0 | $0 | $0 | $305,000 | $960,000 | $900,000 | $900,000 | $1.26M |
| Current assets | $110.86M | $124.47M | $144.56M | $165.54M | $189.82M | $211.68M | $233.19M | $257.96M |
| PP&E, net | $8.62M | $9.90M | $11.16M | $12.29M | $13.89M | $15.11M | $16.52M | $17.74M |
| Total assets | $157.39M | $173.70M | $196.95M | $221.10M | $247.94M | $272.28M | $297.87M | $324.60M |
| Current liabilities | $32.34M | $27.63M | $22.50M | $22.93M | $29.58M | $33.27M | $39.89M | $37.31M |
| Total liabilities | $64.20M | $61.13M | $59.17M | $62.51M | $69.49M | $76.45M | $85.21M | $89.74M |
| Shareholders' equity | $93.19M | $112.57M | $137.78M | $158.60M | $178.45M | $195.83M | $212.66M | $234.86M |
| Shares outstanding | 37.81M | 37.78M | 37.65M | 37.62M | 37.55M | 37.53M | 37.38M | 37.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$19.08M | -$19.51M | -$21.18M | -$23.55M | -$21.25M | -$21.25M | -$22.84M | -$26.28M |
| Capital expenditure | -$21,000 | $125,000 | $25,000 | $85,000 | $74,000 | $127,000 | $288,000 | $334,000 |
| Free cash flow | -$19.06M | -$19.64M | -$21.20M | -$23.63M | -$21.33M | -$21.38M | -$23.13M | -$26.61M |
| Investing cash flow | $16.16M | $33.17M | $3.99M | $32.37M | $27.36M | $19.07M | $24.73M | $28.55M |
| Financing cash flow | $0 | $67,000 | -$27,000 | $74,000 | -$187,000 | -$166,000 | -$77,000 | $0 |
| Depreciation & amortization | $1.25M | $1.26M | $1.27M | $1.30M | $1.32M | $1.33M | $1.36M | $1.46M |
| Stock-based compensation | $1.78M | $2.27M | $2.55M | $2.69M | $3.01M | $3.22M | $2.93M | $3.41M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.